Get the Stockscreener App
0.688
1.03%
0.007
VolitionRX Ltd stock is traded at $0.688, with a volume of 151.69K.
It is up +1.03% in the last 24 hours and down -6.93% over the past month.
VolitionRX Limited, a life sciences company, engages in the development of blood tests to help diagnose a range of cancers worldwide. The company develops 39 epigenetic Nu.Q blood assays based on its Nucleosomics biomarker discovery platform. VolitionRX Limited is based in Singapore.
See More
Previous Close:
$0.681
Open:
$0.67
24h Volume:
151.69K
Relative Volume:
0.64
Market Cap:
$71.54M
Revenue:
$1.29M
Net Income/Loss:
$-29.87M
P/E Ratio:
-1.9111
EPS:
-0.36
Net Cash Flow:
$-14.70M
1W Performance:
-0.99%
1M Performance:
-6.93%
6M Performance:
+24.52%
1Y Performance:
+12.77%
1-Day Range:
$0.67
$0.6928
1-Week Range:
$0.66
$0.72
52-Week Range:
$0.3951
$0.94
VolitionRX Ltd Stock (VNRX) Company Profile
Name
VolitionRX Ltd
Sector
Industry
Phone
646 650 1351
Address
No. 24-05 Shaw Centre, 1 Scotts Road, Singapore, TX
Compare VNRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VNRX
VolitionRX Ltd
|
0.688 | 72.32M | 1.29M | -29.87M | -14.70M | -0.36 |
|
TMO
Thermo Fisher Scientific Inc
|
499.99 | 184.10B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
211.80 | 149.66B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
645.55 | 51.03B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
121.63 | 33.56B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
191.15 | 32.73B | 15.70B | 1.24B | 2.01B | 6.91 |
VolitionRX Ltd Stock (VNRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-08-25 | Initiated | H.C. Wainwright | Buy |
| Feb-01-23 | Downgrade | The Benchmark Company | Buy → Hold |
| Feb-17-22 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-10-21 | Initiated | Cantor Fitzgerald | Overweight |
| May-16-18 | Initiated | Maxim Group | Buy |
| May-14-18 | Reiterated | The Benchmark Company | Buy |
| Sep-07-16 | Reiterated | Rodman & Renshaw | Buy |
| Feb-01-16 | Initiated | Rodman & Renshaw | Buy |
View All
VolitionRX Ltd Stock (VNRX) Latest News
Combining machine learning predictions for VolitionRx LimitedJuly 2025 Trends & Free Real-Time Market Sentiment Alerts - Newser
Can VolitionRx Limited rally from current levelsWeekly Trade Recap & Weekly Return Optimization Alerts - Newser
Is VolitionRx Limited stock entering bullish territoryEarnings Risk Report & Consistent Profit Focused Trading Strategies - Newser
Order flow analysis tools used on VolitionRx LimitedEarnings Recap Report & Verified Chart Pattern Trade Signals - Newser
Developing predictive dashboards with VolitionRx Limited dataJuly 2025 Spike Watch & Low Risk Profit Maximizing Plans - Newser
Analyzing drawdowns of VolitionRx Limited with statistical tools2025 Breakouts & Breakdowns & Technical Pattern Recognition Alerts - Newser
Custom strategy builders for tracking VolitionRx LimitedDollar Strength & Risk Managed Investment Strategies - Newser
Key resistance and support levels for VolitionRx LimitedQuarterly Market Summary & Stepwise Swing Trade Plans - Newser
Using data tools to time your VolitionRx Limited exitJuly 2025 Final Week & Verified Momentum Stock Watchlist - Newser
Comparing VolitionRx Limited in custom built stock radarsPortfolio Risk Report & Safe Swing Trade Setup Alerts - Newser
Has VolitionRx Limited found a price floorGold Moves & Safe Capital Investment Plans - Newser
VolitionRx Limited stock outlook for YEARWeekly Trade Report & Community Consensus Picks - Newser
Real time social sentiment graph for VolitionRx LimitedJuly 2025 WrapUp & Free Daily Entry Point Trade Alerts - Newser
Relative strength of VolitionRx Limited in sector analysisMarket Growth Summary & Free Fast Gain Swing Trade Alerts - Newser
VolitionRx Limited stock daily chart insightsQuarterly Profit Review & Real-Time Stock Entry Alerts - Newser
D. Boral Capital Reiterates “Buy” Rating for VolitionRx (NYSE:VNRX) - Defense World
Volitionrx Ltd earnings missed by $0.01, revenue fell short of estimates - Investing.com Nigeria
VolitionRX Q2 2025 Earnings Call Highlights: Revenue Growth, Strategic Advances, and Cash Challenges - AInvest
VolitionRx Limited (AMEX:VNRX) Q2 2025 Earnings Call Transcript - Insider Monkey
VolitionRX Ltd (VNRX) Q2 2025 Earnings Call Highlights: Revenue Growth and Strategic Advances ... By GuruFocus - Investing.com Canada
VolitionRX Ltd (VNRX) Q2 2025 Earnings Call Highlights: Revenue Growth and Strategic Advances ... - Yahoo Finance
VolitionRx Limited stock retracement – recovery analysisMarket Growth Review & Fast Exit and Entry Trade Guides - Newser
Using AI based signals to follow VolitionRx LimitedWeekly Trade Summary & AI Powered Buy and Sell Recommendations - Newser
VolitionRx Reports Q2 2025 Financial Results and Strategic Advancements - AInvest
VolitionRx Reports Q2 2025 Financial Results and Strategic Progress - TipRanks
VolitionRx Limited Forms Double Bottom Pattern — Eyes on BreakoutEarnings Recap Report & Fast Moving Stock Trade Plans - classian.co.kr
Earnings call transcript: VolitionRx Q2 2025 sees revenue rise, stock dips - Investing.com
VolitionRX Q2 Earnings: $6.3M Loss, $406.7K RevenueNews and Statistics - IndexBox
VolitionRX: Q2 Earnings Snapshot - The Wilton Bulletin
VolitionRx : Corporate Presentation August 2025 - MarketScreener
VolitionRX Q2 2025 Earnings Call Transcript - MarketBeat
VolitionRX's Strategic Momentum in Human Diagnostics: Licensing Deals as a Catalyst for Growth - AInvest
VolitionRX Q2 2025 Earnings Preview: Revenue and Earnings Estimates Decline - AInvest
VolitionRX Reports Q2 Earnings with Revenue Growth and Declining Net Loss. - AInvest
VolitionRx Limited Announces Second Quarter 2025 Financial Results and Business Update - Financial Times
Measuring VolitionRx Limited’s beta against major indices2025 AllTime Highs & High Accuracy Swing Trade Signals - Newser
VolitionRX (VNRX) Expected to Announce Earnings on Thursday - Defense World
How moving averages guide VolitionRx Limited tradingReal Trader Watchlist with Entry Targets - Newser
What does recent volatility data suggest for VolitionRx LimitedReversal Pattern Insights with Entry Tips - Newser
VolitionRx Limited Schedules Second Quarter 2025 Earnings Conference Call and Business Update - Yahoo Finance
VolitionRx Earnings: CEO and Medical Chief to Present Q2 Results and Strategic Updates - Stock Titan
What machine learning models say about VolitionRx LimitedBuy/Sell Zone Confirmation Technical Analysis - Newser
What risks could impact VolitionRx Limited stock performanceSwing Entry Insight With Forecast Accuracy - Newser
Visual analytics tools that track VolitionRx Limited performanceIntraday Strategy with Real Time Monitoring - Newser
Analyzing VolitionRx Limited with multi timeframe chartsDownside Control Plan With Support Analysis - Newser
VolitionRx Announces Pricing of $1.2 Million Registered Direct Offering - 富途牛牛
VolitionRX Ltd Stock (VNRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
VolitionRX Ltd Stock (VNRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Reynolds Cameron John | President and CEO |
Aug 05 '25 |
Buy |
0.64 |
78,125 |
50,000 |
2,609,847 |
| Reynolds Cameron John | President and CEO |
Jun 12 '25 |
Buy |
0.59 |
12,500 |
7,372 |
2,331,722 |
| Innes Guy Archibald | Director |
Jun 03 '25 |
Buy |
0.54 |
20,000 |
10,772 |
888,689 |
| Micallef Jacob Vincent | Chief Scientific Officer |
May 19 '25 |
Buy |
0.43 |
50,000 |
21,500 |
426,033 |
| Reynolds Cameron John | President and CEO |
May 19 '25 |
Buy |
0.44 |
20,000 |
8,730 |
2,319,222 |
| Reynolds Cameron John | President and CEO |
Mar 26 '25 |
Buy |
0.55 |
181,818 |
100,000 |
2,299,222 |
| Innes Guy Archibald | Director |
Mar 26 '25 |
Buy |
0.55 |
181,818 |
100,000 |
868,689 |
| Innes Guy Archibald | Director |
Dec 09 '24 |
Buy |
0.57 |
174,764 |
100,000 |
617,085 |
| STILL TIMOTHY I | Director |
Dec 09 '24 |
Buy |
0.57 |
87,382 |
50,000 |
1,487,382 |
| Micallef Jacob Vincent | Chief Scientific Officer |
Dec 09 '24 |
Buy |
0.57 |
43,691 |
25,000 |
394,352 |
4.05%
1.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):